

Mannogem® XL Mannitol USP/EP/JP

Superior Tableability

Mannogem XL is an innovation in directly compressible spray-dried mannitol. XL is designed to deliver a higher level of performance during formulation, manufacture, and patient use; simply a step-change in DC mannitol performance.

Introduction

Tabletability can be defined as the ability of a powder to form a tablet of adequate strength when force is applied to that powder¹ and is generally assessed by means of testing the resultant tablet hardness, tensile strength, and friability. For conventional swallow tablets, a tensile strength of > 1.7MPa² is generally seen as the minimum requirement to show adequate tablet robustness.

Background

Studies were undertaken comparing the tabletability of Mannogem XL to a standard spray dried mannitol competitor product. Tablets were formulated with non-direct compressible APAP chosen as a difficult-to-tablet model compound and compressed using 0.551" FFBE tooling to a tablet weight of 500 mg. Samples were taken at the various compression forces and tested to evaluate tensile strength and friability. The data are presented in Figures 1 and 2 below.




Figure 1: Tablet tensile strength (MPa) versus compression force (kN) for Mannogem XL and a competitor spray dried mannitol at 15% drug loading.




Figure 2: Tablet friability (%) versus tablet hardness (kPa) for Mannogem XL and a competitor spray dried mannitol at 15% drug loading.

Results

Data show a 25% increase in the tabletability of the formulation when using Mannogem XL at 15% drug loading. A completely linear profile for tensile strength versus compression force indicates a robust formulation that is not prone to tablet problems such as capping.

Tablet robustness is a key Critical Quality Attribute for any formulation and is assessed in terms of both tensile strength as above but also in terms of friability. An ideal formulation will have a requisite high tensile strength and associated low friability at a range of compression forces. Formulations based on Mannogem XL achieve the requisite target for swallow tablets of 1.7MPa TS at lower compression forces than for other mannitols and retain low friability. Data in Figure 2 show good friability over a range of tablet hardness when using XL vs competitive product. Such formulations can be considered robust and therefore less prone to scale-up issues or failures during manufacture.

Mannogem XL has superior tabletability to other conventional spray dried mannitols, leading to the possibility of higher drug loadings in more robust tablets. This has multiple benefits:

Patients

Smaller, less friable tablets

Formulators

Simpler and quicker development that is less prone to scale up issues

Manufacturers

Faster speeds, at lower compression forces and less failures improve productivity, cost efficiency, and reduced tooling wear and tear

References

1. Compression behaviour of orthorhombic paracetamol. Etienne Joiris, Piera Di Martino, Christophe Berneron, Anne-Marie Guyot-Hermann and Jean Claude Guyot. Pharm Research Vol 15 No. 7 1998.
2. Developing Solid Oral Dosage Forms 2nd Edition, Pharmaceutical Theory and Practice, p905 Edited by Qiu Y, Chen Y, Zhang G, Yu L and Mantri R.U 2017. Carino, G. and Mathiowitz, E. Oral insulin delivery, Adv. Drug Del. Rev. 35, 249-257 (1999).

OUR PRODUCTS AND SERVICES CAN HELP YOU TO SOLVE THE MOST CHALLENGING FORMULATION PROBLEMS— EFFICIENTLY, COST-EFFECTIVELY AND WITH A FOCUS ON SERVICE.

ANTACID ACTIVES

The global leader in immediate-relief antacid actives, we specialize in aluminum, magnesium, calcium products, and preformulated solutions for the production of antacid suspensions and tablets.

DRUG DELIVERY SYSTEMS

A full spectrum of ODT products, services, and technologies to support every stage of your product life cycle.

TASTE-MASKED ACTIVES

Our Actimask® technology provides an excellent taste barrier and mouthfeel without hindering API release and onset of therapeutic relief.

FUNCTIONAL EXCIPIENTS

Ingredients and formulation expertise to support a wide range of patient friendly dosage forms.

VACCINE ADJUVANTS

Years of expertise in aluminum hydroxide chemistry ensure our vaccine adjuvants exhibit a very regular profile in terms of compliance, morphology, particle size distribution, and protein adsorption capacity.

DRUG DEVELOPMENT SERVICES

Our complete drug development and testing service can provide unique options to energize your drug portfolio. No time? Limited resources? We can deliver your project to you.

Americas
SPI Pharma, Inc.
Rockwood Office Park
503 Carr Rd., Suite 210
Wilmington, DE 19809

Europe/Middle East/ Africa
SPI Pharma SAS
Chemin du Vallon du Maire
13240 Septemes-Les Vallons
France

Asia/Pacific
SPI Pharma, Inc – India Branch
21 B, Veerasandra Industrial Area
Hosur Road, Bangalore – 560100
Karnataka, India

Australia Distribution Company
Anzchem
1 Braidwood Street
Enfield NSW 2136
Australia

www.spipharma.com



Contact Us:
salesinfo@spipharma.com

© SPI Pharma 2019. All trademarks are the property of SPI Pharma. The information contained in this document is proprietary to SPI Pharma and may not be used or disseminated inappropriately. The information and recommendations contained herein are to the best of SPI Pharma, Inc.'s knowledge reliable and accurate. Any recommendations are made without warranty, either implied or expressed, due to the variations in equipment, conditions, and methods which may be used in commercially processing the products. No warranties of any kind are made, express or implied, including those of merchantability and fitness for particular purpose, other than the products conform to current standard specifications. SPI Pharma, Inc. makes no warranty that the use of the products or formulations provided by SPI Pharma, Inc. will not infringe any trademark, trade name, copyright, patent or other rights held by any third party when used in customer's application. SPI Pharma, Inc. shall not be liable for loss of profit or for incidental, special or consequential loss or damages.

Order# SPI-EXC-MGM-0900-01201900
01-2019 | All rights reserved